secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001213900-23-084735
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada reports Q3 net loss $22.0M; cash $106.3M; REL-1017 Phase 3 enrollment on track
--------------------------------------------------------------------------------

- Q3 net loss $22.0M ($0.73/share) vs $39.4M ($1.31) YoY.
- R&D expense $10.5M, down from $30.5M due to Reliance I/III completion.
- Cash and equivalents $106.3M at Sep 30, 2023 vs $148.3M at Dec 31, 2022.
- Phase 3 REL-1017 trials for MDD: Reliance II enrollment on track for H1 2024; Relight for H2 2024.
- Psilocybin program: Phase 1 in steatotic liver disease to start early 2024, Phase 2a planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023084735/0001213900-23-084735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023084735/ea187924-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-084735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer